大冢和灵北长效版抗精神病药物Abilify Maintena获欧盟批准。 2013年11月25日讯 /生物谷BIOON/ --大冢（Otsuka）和灵北（Lundbeck）11月21 ...

大冢和灵北抗精神病药物Abilify Maintena获加拿大批准，用于精神分裂症的维持治疗。 2014年2月14日讯 /生物谷BIOON/ --大冢（Otsuka ...

日前，大冢制药（Otsuka Pharmaceutical）和灵北（Lundbeck）联合宣布，美国FDA已经批准了阿立哌唑长效注射剂（aripiprazole，商品名为Abilify Asimtufii）的新药申请（NDA），用于治疗成人精神分裂症或作为双相1型障碍患者的单药维持治疗。根据新闻稿介绍，本次获批的阿 ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced that the FDA has approved Abilify Maintena (aripiprazole) for extended-release injectable ...

The study's primary endpoint showed Abilify Maintena significantly delayed the time to recurrence of any mood episode in adults having a manic episode at screening vs. placebo. Otsuka and Lundbeck ...

重磅炸弹药物的成功，往往伴随着高昂的研发投入和独占性专利保护。随着这些药物的专利到期，制药公司不仅面临着竞争加剧的挑战，还需要应对市场重新洗牌、价格下降和创新压力等复杂问题。 近期，笔者盘点了10款将在2024年有部分专利到期的「重磅炸弹」 ...

Settlement Approval Hearings Scheduled in Ontario and Québec for December 20, 2024 and January 8, 2025 and Certification of Ontario Action This notice was approved by the Ontario Superior Court of ...